期刊文献+

CT引导下经皮穿刺囊内灌注顺铂治疗复发性卵巢癌疗效观察 被引量:4

下载PDF
导出
摘要 目的 探讨CT引导下经皮粗针穿刺置管灌注顺铂治疗复发性卵巢癌的临床效果。方法 对13例选择卵巢浆液性囊腺癌术后复发患者采用CT引导下经腹皮粗针穿刺卵巢肿瘤,置管后灌注顺铂20 mg,每周1次,持续4周后拔管。治疗1个月后,复查血清CA125及胸腹盆腔CT,依据RECIST最新疗效评价标准评价临床疗效。随访2年,观察无进展生存期。结果 13例患者近期有效率为92.3%(12/13)。随访2年,无进展生存期为5~24个月,中位无进展生存期为12.6个月。结论 CT引导下经皮粗针穿刺置管囊内灌注顺铂治疗复发性卵巢癌临床疗效较好,不良反应少。
出处 《山东医药》 CAS 2014年第22期55-56,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

  • 1Dinh P, Hamett P, Piccart Gebhart M J, et al. New thrapied for ovrain cancer: eytotoxies andmoleeularly targeted agents [ J ]. Crit Rev Oneol Hematol, 2008,67 ( 2 ) : 103-112.
  • 2袁莉,袁新荣,邸媛媛,李红薇,樊龙中.CA-125对上皮性卵巢癌患者预后的评估[J].广州医学院学报,2011,39(3):47-50. 被引量:7
  • 3Deneve JL, Choi J, Gonzalez RJ, et al. Chemosaturation with per- cutaneous hepatic perfusion for unresectable isolated hepatic metas- tases from sarcoma. Cardiovasc Intervent Radiol [J]. Cardiovasc Intervent Radiol, 2012,35 (6) : 1480-1487.
  • 4Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carbopla- tin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG[ J]. J Clin Oncol, 2006,24 (29) :4699-4707.
  • 5潘一红,陶俊贞,吕荣伟,金芙蓉,林慧敏,周丹红,陶德友.吉西他滨联合卡铂在复发性上皮性卵巢癌治疗中的应用[J].上海交通大学学报(医学版),2011,31(4):481-483. 被引量:6
  • 6朱笕青,陈雅卿,羊正炎,张平.顺铂和依托泊苷及六甲蜜胺联合治疗铂类敏感复发性卵巢癌的临床分析[J].肿瘤防治杂志,2005,12(12):938-940. 被引量:2
  • 7Aghajanian C, Blank S, Golf BA, et al. OCEANS: a random- ized, double-blind, placebo-controlled phase III trial of chemother- apy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012,30(17) :2039-2045.
  • 8Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment [ J]. Oncology (Williston Park), 2013,27 (4) :288-294.

二级参考文献28

  • 1潘一红,赵玲萍,林志文.晚期卵巢癌的化学治疗[J].实用中西医结合临床,2006,6(3):89-91. 被引量:3
  • 2Aletti GD,Gostout BS,Podratz KC,et al.Ovarian cancer surgical resectability:relative impact of disease,patient status,and surgeon[J].Gynecol Oncol,2006,100(26):33-37.
  • 3Bast RC,Jr.,Badgwell D,Lu Z,Marquez R,Rosen D,Liu J,et al.New tumor markers:CA125 and beyond[J].Int J Gynecol Cancer,2005,15 (Suppl 3):274-281.
  • 4Sturgeon CM,Duffy M J,Stenman UH,et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular,prostate,colorectal,breast,and ovarian cancers[J].Clin Chem,2008,54(12):e11-79.
  • 5Cooper BC,Sood AK,Davis CS,et al.Preoperative CA 125levels:an independent prognostic factor for epithelial ovarian cancer[J].Obstet Gynecol,2002,100 (12):59-64.
  • 6Markman M, Bookman M A. Second-line treatment of ovarian cancer[J]. Oncologist, 2000,5(1):26-35.
  • 7Miller A B, Hoogstraten B, Staquet M,et al. Reporting results of cancer treatment[J]. Cancer, 1981,47(1):207-214.
  • 8Rustin G J, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) [J]. J Natl Cancer Inst, 2004,96(6):487-488.
  • 9Vergote I, Rustin G J, Eisenhauer E A, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup[J]. J Natl Cancer Inst, 2000,92(18):1534-1535.
  • 10Frasci G,Comella G,Comella P,et al. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (Vp-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study[J]. Gynecol Oncol, 1995,58(1):68-73.

共引文献12

同被引文献51

  • 1陈鲁,朱笕青.卵巢癌的巩固治疗[J].国外医学(妇产科学分册),2006,33(2):135-138. 被引量:5
  • 2吴湖炳,王全师,王明芳,郭晓君.PET/CT显像在探测卵巢癌术后复发、转移中的应用[J].中华核医学杂志,2006,26(4):197-200. 被引量:23
  • 3蔡定均,周奇志,宋开源,赵纪岚,魏焦禄,刘旭光.电针对非光性授时因子导引节律作用的影响[J].成都中医药大学学报,2006,29(3):27-29. 被引量:13
  • 4谢科卡,杨丹柯.针刀、火针二联疗法治疗甲瘤46例临床观察[J].科学之友,2007(04B):262-262. 被引量:1
  • 5汤洁,蔡树模,黄啸,李子庭,臧荣余.复发性卵巢癌的化放疗研究[J].肿瘤,2007,27(8):638-641. 被引量:8
  • 6Hebel,CB, Behrendt, FF, Heinzel,A. et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer[J].European Journal of Radiology, 2014,83(3):463-467.
  • 7Ki tajima, K, Ueno, Y, Suzuki, K et al. Low-dose non-enhanced CT versus full-dose contrasteahanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence[l]. European Journal of Radiology, 2012,81(ll):3557-3562.
  • 8Ashraf Anas Zytoon, Koji Murakami, Hazem Eid et al. High impact of FDG-PET/ CT in diagnostic strategies for ovarian cancer. [J].Acta Radiologica, 2013,54(3):340- 348.
  • 9Liu, J.,Wang, S.,Linguraru, M. G. et al. Tumor sensitive matching flow: A variational method to detecting and segmenting perihepatic and perisplenic ovarian cancer metastases o11 contrast-enhanced abdominal CT[J].Nedical image analysis, 2014, 18(5): 725-739.
  • 10Du, X.-L, Jiang, T, Sheng, X.-6 et al. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer[J].Enropean Journal of Radiology, 2012, 81(11): 3551-3556.

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部